AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings

Shutter2U Investment Overview In the first of my two most recent pieces of coverage for Seeking Alpha on AstraZeneca PLC (NASDAQ:AZN), the Anglo / Swedish Pharma giant, I gave the company and its stock a “buy” recommendation in February. This was after a sell-off in response to a Q4 2023 earnings miss created a buying opportunity. Then, in late May, I gave it a “hold” recommendation, shortly after the company had revealed ambitious plans to exceed $80bn in top-line revenues by 2030. AstraZeneca stock is ...